Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2026-07-21		NCT05297617

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Agendia	4
UNICANCER	111

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Hospitalier Universitaire de Limoges	Limoges	France	4
Institute Gustave Roussy	Villejuif	France	4

Clinical trials